{"id":"arexvy-abrysvo","safety":{"commonSideEffects":[{"rate":"40–50","effect":"Injection site pain"},{"rate":"20–30","effect":"Myalgia"},{"rate":"15–25","effect":"Fatigue"},{"rate":"15–20","effect":"Headache"},{"rate":"10–15","effect":"Injection site swelling"},{"rate":"5–10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These vaccines contain a stabilized prefusion form of the RSV fusion (F) glycoprotein, which is a key target for neutralizing antibodies. By presenting this antigen, the vaccines stimulate both humoral and cellular immune responses that protect against RSV infection and disease severity. They are indicated for prevention of RSV-caused lower respiratory tract disease in older adults and infants.","oneSentence":"AREXVY and ABRYSVO are recombinant glycoprotein F (RSVpreF3) vaccines that elicit immune responses against respiratory syncytial virus (RSV) to prevent RSV disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:35.723Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older"},{"name":"Prevention of RSV-caused lower respiratory tract disease in infants born to vaccinated pregnant women"}]},"trialDetails":[{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":"Preventable Disease, Vaccine","enrollment":600},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06077149","phase":"PHASE4","title":"Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2023-11-07","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"AREXVY, ABRYSVO","genericName":"AREXVY, ABRYSVO","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AREXVY and ABRYSVO are vaccines that have been studied in clinical trials for various conditions, including Lymphoma, Preventable Disease, Vaccine, and Respiratory Syncytial Virus (RSV), and have been administered in combination with Fluzone, Shingrix, and Flucelvax. The vaccines are being investigated in a study titled \"Vaccine Responses in Patients With B Cell Malignancies\" at the National Institutes of Health Clinical Center.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}